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Edited by Beat ImhofAbstract There is increasing evidence that epithelial–mesen-
chymal transition (EMT) plays a critical role in cancer metasta-
sis. Butein is a polyphenolic compound, which has been found to
exhibit anti-proliferation eﬀects on cancer cells. Here, we report
that in addition to its function as an anti-proliferation agent, bu-
tein can inhibit migration and invasion through the ERK1/2 and
NF-jB signaling pathways in human bladder cancer cells, and
this inhibitory eﬀect may be associated with reversal of EMT.
These results were further conﬁrmed by RNAi-mediated suppres-
sion of NF-jB, which partly reverses EMT and inhibits cell inva-
sive ability in vitro. These results suggest a novel function of
butein as an invasion inhibitor in bladder cancer.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cancer metastasis, rather than primary tumors, is responsi-
ble for most cancer deaths [1]. Epithelial–mesenchymal transi-
tion (EMT) was originally recognized as an important event of
embryogenesis and was found to participate in mesoderm and
neural crest formation. Recently, accumulating evidence sug-
gested that EMT is also reactivated and plays a critical role
in the metastasis process of human cancers [2,3]. Therefore,
strategies that regulate EMT attract increasing attention.
3,4,2 0,4 0-Tetrahydroxychalcone (butein) is a polyphenolic
compound, which can be extracted from stembark of cashews
and Rhus verniciﬂua Stokes, and used as a food additive and a
traditional herbal medicine. Previous studies suggested that
butein exhibit anticancer activity; butein could induce apopto-
sis in human promyelocytic leukemia cells [4] and B16 mela-
noma cells [5]. In vitro, butein can suppress the proliferation
of many human cancers, including breast carcinoma, colon
carcinoma, osteosarcoma, and hepatic stellate cells [6–10].
But the anticancer mechanisms of butein are not fully under-
stood.
BLS-211 and BLX-211 cell lines were previously established
by our laboratory and derived from the same surgical sample
of a 55-year-old male patient with gradeII transitional cell car-
cinoma (TCC) of the bladder. These two cell lines had similar*Corresponding author.
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doi:10.1016/j.febslet.2008.04.046chromosomal alterations [11], but showed remarkable
diﬀerences in cell morphology and biological characteristics.
BLS-211 cells showed mesenchymal-like phenotype, while
BLX-211 cells displayed epithelial phenotype. Furthermore,
BLS-211 cells were more motile and invasive than BLX-211
cells. Using suppression subtractive hybridization (SSH), we
previously found BLS-211 cells express mesenchymal proteins,
such as vimentin, N-cadherin, but BLX-211 cells express epi-
thelial marker, such as E-cadherin [12]. Here, we used these
two cell lines to assess the anticancer eﬀects of butein, and to
provide possible mechanisms.2. Materials and methods
2.1. Cell culture
BLS-211 and BLX-211 cells were cultured with RPMI 1640 medium
(Gibco-BRL, Gaithersburg, MD, USA) supplemented with 10% bo-
vine calf serum, 100 U/ml penicillin and 100 lg/ml streptomycin, and
maintained at 37 C in an incubator with a humidiﬁed atmosphere
of 5% CO2.2.2. Western blot analysis
Brieﬂy, cells were lysed with RIPA buﬀer containing protease inhib-
itor. Equal amounts of protein (10–30lg) were separated by 10% SDS–
PAGE, electrophoretically transferred to nitrocellulose membrane, the
membrane was then incubated with the relevant primary antibodies
against p44/42 MAPK, phospho-p44/42 MAPK (Cell Signaling Tech-
nology, Danvers, MA, USA), NF-jB, Vimentin, E-cadherin (Santa
Cruz, CA) or b-actin (Biosynthesis Biotechnology, Beijing, China)
and appropriate secondary antibodies (Pierce Biotech, USA), signals
were visualized by ECL reagent.2.3. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared according to the protocol of Nuclear
Extraction kit (KEYGEN Biotechnology). The sequence of the URE
NF-jB-containing oligonucleotide as follows: 5 0-GAT-
CCAAGTCCGGGTTTTCCCCAACC-3 0. As the loading control,
the octomer-1 oligonucleotide has the following sequence: 5 0-
TGTCGAATGCAAATCACTAGAA-3 0. Electrophoretic mobility
shift assay (EMSA) was carried out according to the protocol accom-
panying EMSA/Gel-Shift kit (Beyotime Biotechnology). The speciﬁc-
ity of binding was examined by competition with the unlabeled
probes. For supershift assays, the nuclear extract (5 lg) was incubated
at room temperature for 20 min with 32P-labeled probe and antibodies
against p65 (Santa Cruz) (3 ll). DNA/nuclear protein complexes were
separated by electrophoresis on a native 6% acrylamide gel, and the gel
was subjected to autoradiography.
2.4. Immunoﬂuorescent assay
Cells were grown on glass coverslips for 24 h and ﬁxed with metha-
nol for 10 min at 20 C. For permeabilization, cells were incubated
with 0.1% Triton X-100 for 5 min at room temperature and then
washed three times in PBS. Cells were blocked with goat serum forblished by Elsevier B.V. All rights reserved.
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Fig. 1. (A) Morphology of BLX(E) and BLS(M) cells by light
microscope. (B) Western blot assays show that BLX(E) cells express E-
cadherin (an epithelial marker), while BLS(M) cells overexpress
vimentin (a mesenchymal marker). (C) The signiﬁcant diﬀerence of
NF-jB activity between BLX(E) and BLS(M) cells by EMSA.
1822 LiRui Zhang et al. / FEBS Letters 582 (2008) 1821–182830 min at room temperature, incubated with primary antibody for
vimentin, E-cadherin and b-catenin (Santa Cruz) (1:100) diluted in
PBS overnight, and then incubated with ﬂuorescent secondary anti-
body for 30 min at room temperature. The specimens were observed
under ﬂuorescent microscope.
2.5. Migration and invasion assays
Cell migration and invasion were tested using a transwell chamber
migration assay (8 lM pore size membrane, millipore) or invasion as-
say (matrigel-coated membrane). cells were seeded in serum-free med-
ium into the upper chamber and allowed to migrate or invade toward
media containing 20% FCS as a chemoattractant in the lower chamber
for 8 h (migration assay) or 22 h (invasion assay), cells in the upper
chamber were carefully removed using cotton buds, and cells at the
bottom of the membrane were ﬁxed and stained with Giemsa. Quanti-
ﬁcation was done by counting the stained cells.
2.6. Scratch assay
Cells were grown to 90% conﬂuence in six-well culture plates. Cell
monolayers were wounded by manually scraping the cells with a
200 ll plastic pipet tip. Debris was removed from the culture by wash-
ing with phosphate-buﬀered saline (PBS) twice, and the cells were then
maintained at 37 C in an incubator. Images were captured immedi-
ately after wounding and 24 h post wounding, and wound closure
was monitored with microscopy. Wound sizes were veriﬁed with an
ocular ruler to ensure that all wounds were the same width at the
beginning of the experiment.
2.7. RNAi
Two shRNAinsert sequences forNF-jBp65 (GenBankaccessionnum-
ber, NM_021975) were as follows: 50-gattcGGACATATGAGACCTT-
CAAttcaagagaTTGAAGGTCTCATATGTCCttttttggaaa- 3 0 and 5 0-
gattcCCCCTTCCAAGTTCCTATAttcaagagaTATAGG-AACTTG-
GAAGGGGt tttttggaaa-3 0. As a negative control, the empty vector of
the pRNAT-U6.1/Neo (GenScript Corp, Piscataway, NJ, USA) was
used. Sense and antisense oligonucleotides were annealed and subcloned
into the shRNA expression vector pRNAT-U6.1/Neo. BLS-211 cells
were transfected using Lipofectamine 2000 reagent(Invitrogen) accord-
ing to the manufacturers instruction, and then selected with 150 lg/ml
G418(Gibco). Individual clones were picked, based on GFP expression
and neomycin resistance, and maintained in 1640 medium containing
50 lg/ml G418.
2.8. RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen Life Tech-
nologies) and quantitated by absorbance at 260 nm. cDNA synthesis
was conducted using ImProm-II Reverse Transcription System (pro-
mega) according to manufacturers instructions. All primers were de-
signed using Oligo6.0 software. The primer sequences are listed as
follows (Table 1): F, forward primer; R, reverse primer.
2.9. Statistical analysis
The results were presented as means ± S.D. of three replicate assays.
All statistical analyses were performed using the SPSS13.0 software.
Diﬀerences between diﬀerent groups were assessed using ANOVA orTable 1
The primer sequences for RT-PCR
Gene length Primer
Snail F5 0-TCTAGGCCCTGGC
(GenBank accession number NM_005985) R5 0-ACATCTGAGTGGG
Slug F5 0-ATGCATATTCGGA
(GenBank accession number NM_003068) R5 0-AGATTTGACCTGT
Zeb1 F5 0-TGGCGATAGATGG
(GenBank accession number NM_030751) R5 0-AACTTGAAGTTGG
Zeb2 F5 0-TGCGACATAAATA
(GenBank accession number NM_014795) R5 0-TGTGCTGCGAGTA
Twist F5-GGCGGCCAGGTAC
(GenBank accession number NM_000474) R5 0-GCTAGTGGGACGC
18SrRNA F5 0-CAGCCACCCGAGA
(GenBank accession number M-10098) R5 0-TAGTAGCGACGGGDunnett t-test. P < 0.05 was considered to indicate statistical signiﬁ-
cance.3. Result
3.1. BLS-211 cells show mesenchymal-like phenotype but BLX-
211 cells epithelial phenotype
BLX-211 cells are polyhedral and grow in a tightly con-
nected manner; while BLS-211 cells are spindle-shaped and
lose intercellular junctions (Fig. 1A). We further examined
the EMT-associated molecular by Western blot analysis. As
shown in Fig. 1B, BLX-211 cells (called BLX(E) hereafter) ex-
press an epithelial marker E-cadherin; in contrast, BLS-211
cells (called BLS(M) hereafter) overexpress a mesenchymal
marker vimentin and lose E-cadherin. Furthermore, we found
higher level of NF-jB activity in BLS(M) compared to
BLX(E) cells by EMSA (Fig. 1C).
3.2. Butein reduced phosphorylation of ERK1/2
Our data indicated that butein inhibited cell proliferation
and clonogenecity of BLS(M) and BLX(E) in dose-dependent
manner, but when butein <20 lM, there was no signiﬁcantPosition Product (bp)
TGCTACAA-30 638–768 131
TCTGGAGGTG-3 0
CCCACACATTAC-3 0 690–847 158
CTGCAAATGCTC-30
TAATG-3 0 1275–1465 209
CTAGGC-30
CGAACA-30 3524–3684 177
CGAG-3 0
ATCGACTT-30 804–943 157
GGACAT-30
TTGAGCA-30 1565–1816 253
CGGTGTG-3 0
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up to 48 h post-exposure time(data not shown). Thus, we
chose butein at concentrations of 1–20 lM for subsequent
experiments. To analyze the anti-proliferation mechanisms of
butein, BLS(M) and BLX(E) cells were treated with butein
(20 lM) for various time periods. Phosphorylation levels of
ERK1/2 were obviously decreased in time-dependent manner
(Fig. 2A; *P < 0.01 compared with control group), but the
expression of ERK1/2 had no obvious changes.3.3. Butein inhibited NF-jB activity
Whether butein alone could inhibit constitutive NF-jB
activity in BLS(M) cells was investigated. BLS(M) cells were
treated with butein (20 lM) for various time periods and then
analyzed for NF-jB activity. As shown in Fig. 2B, butein
inhibited the constitutive NF-jB activity of BLS(M) cells in
time-dependent manner. We next assessed the eﬀects of butein
on the NF-jB activity induced by TNF-a in BLX(E) cells.
BLX(E) cells were ﬁrst pretreated with butein for various
times, then exposed to 5 ng/ml TNF-a for 1 h. The results indi-p-E
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Fig. 2. (A) Eﬀects of butein on ERK1/2 activation. BLS(M) and BLX(E) cel
analysis was conducted. Results were quantiﬁed by densitometry analysis of b
control group. (B) Suppression eﬀect of butein on constitutive NF-jB activity
induced NF-jB activation of BLX(E) cells by EMSA. Oct-1 as loading con
unlabeled probes (cold probes) and supershift assays.cated that butein could suppress not only constitutively active
but also inducible NF-jB activity in bladder cancer cells
(Fig. 2C).
3.4. Butein reversed mesenchymal-like phenotype of BLS(M)
cells
It has been demonstrated that both ERK1/2 and NF-jB
pathways were involved in EMT [2,3]. Based on the above
observations that butein could inhibit both phosphorylation
of ERK1/2 and constitutive NF-jB activity, we then asked
whether butein could reverse mesenchymal-like phenotype
of BLS(M) cells. After 48 h of butein (20 lM) treatment,
we observed morphologic changes of BLS(M) cells from
elongated morphology to rounded epithelial-like cells. Using
immunoﬂuorescence and western blot assay, we tested
whether the morphologic changes correlated with EMT-asso-
ciated proteins. Results showed downregulation of vimentin,
but gain of E-cadherin in butein-treated BLS(M) cells com-
pared to untreated control cells (Fig. 3A and B). Moreover,
we found butein promote b-catenin membrane localization
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Fig. 3. Butein reversed mesenchymal-like phenotype of BLS(M) cells. BLS(M) cells were treated with butein (20 lM) for the indicate times. (A)
Immunoﬂuorescence analysis. (B) Western blot analysis showed reduced expression of vimentin and gain of E-cadherin in butein-treated cells
compared to untreated control cells. Moreover, immunoﬂuorescence analysis showed butein promote b-catenin membrane localization. (C) Butein
inhibited the motility and invasion capacity of BLS(M) cells. Representative number of motility or invading cells was counted under the microscope
in ﬁve random ﬁelds at 200·. The diﬀerence was signiﬁcant between butein-treated cells and control cells (*P < 0.05). Results are representative of
three separate experiments. Representative visual ﬁeld of butein-treated cells (right well) compared to Control cells (left well) is shown.
1824 LiRui Zhang et al. / FEBS Letters 582 (2008) 1821–18283.5. Butein suppressed motility and invasion capacity of
BLS(M) cells
In order to study the eﬀect of butein on motility and inva-
sion activity of BLS(M) cells, BLS(M) cells were pretreated
with diﬀerent concentration butein (5,10,20 lM) for 48 h and
seeded on Millicell chambers with uncoated or matrigel-coated
ﬁlters. After 8 h or 22 h of incubation, we investigated both
motility and invasive potential of BLS(M) cells pretreated with
butein (20 lM) were signiﬁcantly inhibited (Fig. 3C;
*P < 0.05), but when butein was 5 lM and 10 lM, there had
no signiﬁcant eﬀect on motility and invasion potential of
BLS(M) cells.
3.6. Butein reverted EMT-like phenotype induced by TNF-a in
BLX(E) cells
Tumor necrosis factor-a (TNF-a), an activator of NF-jB,
has been found to promote EMT in vitro [13]. BLX(E) cells
were continuously cultured in medium containing TNF-a
(5 ng/ml) for 3 and 6 days. TNF-a-induced BLX(E)
cells exhibited more elongated morphology, which resembled
that of cells undergoing EMT. Molecular hallmarks of EMTinclude downregulation of E-cadherin responsible for the loss
of cell–cell adhesion and upregulation of mesenchymal-related
proteins such as vimentin and N-cadherin [2,3]. To test this
possibility, the expression and localization of E-cadherin and
vimentin were determined by Western blot and immunoﬂuo-
rescence analysis, demonstrating reduced expression level and
membrane localization loss of E-cadherin, and nuclear locali-
zation of b-catenin, but increased level of vimentin at 6 days
posttreatment with TNF-a. These data suggested that TNF-
a could induce EMT in BLX(E) cells. We further investigated
whether butein can revert EMT-like phenotype induced by
TNF-a. TNF-a-induced BLX(E) cells were subsequently trea-
ted with butein for 48 h. As a results, the EMT-like phenotype
was partly reverted to epithelial phenotype (Fig. 4A and B),
while removal of TNF-a for 48 h had no obvious eﬀect (data
not shown).
3.7. Suppression of NF-jBp65 by transfection with pRNATu6.1/
Neo encoding p65 shRNA
We constructed two sublines that stably expressed NF-
jBp65 shRNA and one subline that express negative vector
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Fig. 4. Butein reverted EMT-like phenotype induced by TNF-a in BLX(E) cells. BLX(E) cells were continuously cultured in medium containing
TNF-a (5 ng/ml) for 3 and 6 days, and subsequently treated with or without butein (20 lm) for 48 h. (A) Immunoﬂuorescence analysis showed
membrane localization loss of E-cadherin, increased level of vimentin, and nuclear localization of b-catenin at 6 days posttreatment with TNF-a. but
butein reverted the morphologic and molecular changes induced by TNF-a. (B) Western blot analysis showed TNF-a downregulate E-cadherin and
upregulate vimentin, which can be reverted by butein.
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control, respectively. Western blot analysis demonstrated that
NF-jBp65 protein was signiﬁcantly suppressed only in one
subline pRNATp65-1, but there was no diﬀerence between
the parental and mock cells (Fig. 5A; *P < 0.01).
3.8. Knockdown of NF-jBp65 by RNAi reversed mesenchymal-
like phenotype and suppressed motility and invasion
capacity of BLS(M) cells
No obvious morphologic changes were observed when the
mock cells were compared with the parental cells. In sharp
contrast, the shRNAp65-1 cells underwent a signiﬁcant mor-
phologic transformation; the cells acquired a rounded and less
elongated shape (Fig. 5B). Western blot and immunoﬂuores-cence results showed shRNAp65-1 cells acquired E-cadherin
and signiﬁcantly down regulated vimentin (Fig. 5C and D).
In vitro motility and invasion assay were performed. Results
showed both motility and invasive potential of shRNAp65-1
cells appeared signiﬁcantly reduced (Fig. 5E; *P < 0.05).
Scratch-wound assays were also utilized to investigate cell
migration. NF-jBp65 knockdown resulted in decreased motil-
ity of BLS(M) cells; the recovery of wound was signiﬁcantly
delayed in shRNAp65-1 cells (Fig. 5F; *P < 0.05).
3.9. Butein downregulated expression of the genes involved in
EMT
To identify the downstream targets of butein, expression of
the known transcriptional regulators involved in EMT were
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1826 LiRui Zhang et al. / FEBS Letters 582 (2008) 1821–1828analyzed by RT-PCR. We could not detect the expression of
snail in BLS(M) parental cells and butein-treated cells, as well
as shRNAp65 cells (data not shown). Expression of slug, zeb2and twist mRNA were signiﬁcantly downregulated in cells
treated with butein for 48 h compared with the untreated con-
trol cells (P < 0.05), NF-jBp65 knockdown by RNAi pro-
LiRui Zhang et al. / FEBS Letters 582 (2008) 1821–1828 1827duced the similar results (Fig. 6A). Next, we also examined the
expression of MMP9 and MMP2 by Western blot (Fig. 6B),
and found both butein and RNAi targeting NF-jBp65 signif-
icantly reduced MMP9 expression (*P < 0.01 compared with
control group), but had no eﬀect on MMP2.4. Discussion
In this study, utilizing well-characteristic cell lines of bladder
cancer, we have demonstrated a novel anticancer eﬀect of bu-
tein and provided possible mechanisms responsible for their
anti-invasive eﬀect.
The anti-proliferation eﬀect of butein has been well docu-
mented in many types of human cancers [6–10]; our results
indicated that butein inhibited cell proliferation of bladder
cancer in dose-dependent manner, which were in agreement
with previous studies. But the anticancer mechanisms of bu-
tein remain elusive. In this study, we found butein greatly re-
duced the phosphorylation and activation of ERK1/2 in
BLS(M) cells. Extracellular signal-regulated protein kinases
(ERK)1/2 are important members of the mitogen-activated
protein kinase (MAPK) family, which are the key factors
of transmitting cell proliferation signals [14]. ERK1/2 is also
known to be important for the activation of Nuclear factor
jB (NF-jB) [15]. NF-jB is critically involved in the regula-
tion of tumor cell proliferation, apoptosis and oncogenesis
[16]. A recent study suggests that anti-tumor and anti-inﬂam-
matory activities of butein may be mediated in part through
the suppression of the NF-jB activation [17]. Our data fur-
ther demonstrated that butein could suppress not only con-
stitutive but also inducible NF-jB activation in bladder
cancer cells. Therefore, these results suggested that antican-
cer activity of butein may be involved in both ERK1/
2MAPK and NF-jB signaling pathway.
EMT involves diverse signal transduction cascades activated
in response to various growth factors and cytokine. These
pathways converge to promote cell motility, invasiveness,
and metastasis [18]. The Ras pathway has been shown to be
of crucial importance in EMT by both in vitro and in vivo
studies[19,20]. Moreover, in addition to its well-known antiap-
optotic eﬀects, NF-jB has also been implicated in EMT
[13,21–23]. NF-jB is essential for both the induction and
maintenance of EMT in murine mammary carcinoma model
[23]. Since butein signiﬁcantly suppressed both activation of
MAPK pathway and NF-jB activity, we postulated that bu-
tein may reverse EMT. As respected, butein could partly re-
versed mesenchymal-like phenotype of BLS(M) cells as well
as the EMT-like phenotype induced by TNF-a in BLX(E)
cells, which is judged by morphologic and molecular changes
including gain of E-cadherin, reduction of vimentin and mem-
brane localization of b-catenin. b-Catenin is a component of
adherent junctions, links transmembrane protein E-cadherin
to the actin cytoskeleton, and is also a key eﬀector of the
Wnt pathway. The accumulation of free cytoplasmic b-catenin
and/or its translocation to the nucleus trigger epithelial–mesen-
chymal transition [24]. Up-regulation of vimentin can facilitate
pseudopod formation and cytoskeletal remodeling [25]. Dur-
ing EMT, loss of intercellular adhesion and the activation of
the cytoskeleton ultimately enhance motility and invasion.
Reversal of EMT often results in the inhibition of cell metas-tasis ability [23]. We observed the suppression eﬀect of butein
on both migration and matrigel invasion capacity of BLS(M)
cells. Thus, it is possible that butein could suppress the bladder
cancer invasion and metastasis through reversal of EMT.
We performed RNAi targeting NF-jBp65 in BLS(M) cells,
and found NF-jBp65 silencing could obviously inhibit the
migration as well as invasion ability, and partly reverse the
mesenchymal-like phenotype, which were similar to that ob-
served in butein-treated BLS(M) cells. These data further con-
ﬁrmed that the anti-invasion eﬀect of butein may be associated
with the inhibition of NF-jB activity.
Several zinc-ﬁnger transcriptional repressors, including slug,
zeb1, zeb2, and twist, have been reported to reduce E-cadherin
expression and induce EMT [26–29]. Matrix metalloprotein-
ase(MMP)9, as a downstream target of NF-jB, is capable of
degrading the ECM and altering cell–cell and cell–ECM inter-
actions, and has been shown to be associated with cancer inva-
sion and EMT [30]. We subsequently examined expression of
these EMT-associated genes in butein-treated cells and shR-
NAp65-1 cells. Downregulation of slug, zeb2, twist and
MMP9 was demonstrated in both butein-treated and shR-
NAp65-1 cells compare to untreated control cells, suggesting
the decreased expression of these genes by butein is mediated
in part through the inhibition of the NF-jB activity, which
may play an important role in mesenchymal to epithelial tran-
sition induced by butein.
Taken together, our data for the ﬁrst time suggested butein
could inhibit migration and invasion through ERK1/2 and
NF-jB signaling pathway, and this inhibitory eﬀect may be
associated with reversal of EMT. Butein should be considered
as a possible therapeutic agent for inhibiting the metastasis
and invasion of bladder cancer. Further studies in vivo will
be required to assess the potential of butein in treatment of
cancer.
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